Connecting via Winsock to STN

Welcome to STN International! Enter x:X

LOGINID:SSPTABEM1624

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JUL 28	CA/CAplus patent coverage enhanced
NEWS	3	JUL 28	EPFULL enhanced with additional legal status information from the epoline Register
NEWS	4	JUL 28	IFICDB, IFIPAT, and IFIUDB reloaded with enhancements
NEWS	5	JUL 28	STN Viewer performance improved
NEWS	6	AUG 01	INPADOCDB and INPAFAMDB coverage enhanced
NEWS	7	AUG 13	CA/CAplus enhanced with printed Chemical Abstracts page images from 1967-1998
NEWS	8	AUG 15	CAOLD to be discontinued on December 31, 2008
NEWS	9	AUG 15	CAplus currency for Korean patents enhanced
NEWS	10	AUG 27	CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information
NEWS	11	SEP 18	Support for STN Express, Versions 6.01 and earlier, to be discontinued
NEWS	12	SEP 25	CA/CAplus current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances
NEWS	13	SEP 26	WPIDS, WPINDEX, and WPIX coverage of Chinese and and Korean patents enhanced
NEWS	14	SEP 29	IFICLS enhanced with new super search field
NEWS	15	SEP 29	EMBASE and EMBAL enhanced with new search and display fields
NEWS	16	SEP 30	CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents
NEWS	17	OCT 07	EPFULL enhanced with full implementation of EPC2000
NEWS	18	OCT 07	Multiple databases enhanced for more flexible patent number searching
NEWS	19	OCT 22	Current-awareness alert (SDI) setup and editing enhanced
NEWS	20	OCT 22	WPIDS, WPINDEX, and WPIX enhanced with Canadian PCT Applications
NEWS	21	OCT 24	CHEMLIST enhanced with intermediate list of pre-registered REACH substances

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:17:26 ON 04 NOV 2008

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 16:17:33 ON 04 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 3 NOV 2008 HIGHEST RN 1070514-14-5
DICTIONARY FILE UPDATES: 3 NOV 2008 HIGHEST RN 1070514-14-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\STNEXP\Queries\10535268.str





chain nodes :
7 8 9 10 11 12
ring nodes :
1 2 3 4 5 6
ring/chain nodes :
15
chain bonds :
4-7 7-8 7-9 9-10 10-11 11-12
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 4-7 5-6 7-8 7-9 9-10 11-12
exact bonds :

```
10-11
isolated ring systems :
containing 1 :


Match level :
1:Atom  2:Atom  3:Atom  4:Atom  5:Atom  6:Atom  7:CLASS  8:CLASS  9:CLASS  10:CLASS
 11:CLASS  12:Atom  15:CLASS  16:CLASS



L1      STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.


=> s l1
SAMPLE SEARCH INITIATED 16:17:57 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -     7788 TO ITERATE

 25.7% PROCESSED     2000 ITERATIONS                                 2 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:       150470 TO   161050
PROJECTED ANSWERS:               2 TO      322

L2            2 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 16:18:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -   153368 TO ITERATE

100.0% PROCESSED   153368 ITERATIONS                             252 ANSWERS
SEARCH TIME: 00.00.02

L3          252 SEA SSS FUL L1

=> d scan

L3   252 ANSWERS   REGISTRY  COPYRIGHT 2008 ACS on STN
IN   1-Oxa-3-azaspiro[4.5]decan-2-one, 3-[1-[2-[(2-
     phenylethenyl)sulfonyl]acetyl]-4-piperidinyl]-
MF   C23 H30 N2 O5 S
```



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Oxazolidinone, 4-phenyl-3-[1-[2-[(2-phenylethenyl)sulfonyl]acetyl]-4-piperidinyl]-
MF C24 H26 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Oxazolidinone, 4-(2-methylpropyl)-3-[1-[2-(phenylsulfonyl)acetyl]-4-piperidinyl]-
MF C20 H28 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Piperidine, 1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-(2-imino-1-piperidinyl)-, mono(trifluoroacetate) (salt) (9CI)
MF C23 H28 Cl N3 O4 S . C2 H F3 O2

CM 1

Absolute stereochemistry.



CM 2

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Pyrimidinone, 1-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]tetrahydro-
MF C22 H26 Cl N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Piperazinone, 1-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-4-methyl-
MF C23 H28 Cl N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3(2H)-Thiazoleacetic acid, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]imino]-5-methyl-, (2Z)-
MF C24 H26 Cl N3 O5 S2
CI COM

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Thiazolecarboxylic acid, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]imino]-2,3-dihydro-3-methyl-, ethyl ester, (2Z)-
MF C25 H28 Cl N3 O5 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-2-methyl-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-
MF C25 H27 Cl N4 O5 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2-dihydro-
MF C30 H39 Cl N4 O5 S Si



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Imidazo[1,2-a]pyridine-3-carboxamide,
N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-
5,6,7,8-tetrahydro-
MF C26 H29 Cl N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN β-Alanine, N-(1-oxobutyl)-, [2-[1-[(2S)-3-[(6-chloro-2-
naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-
oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
MF C31 H36 Cl N5 O8 S

Absolute stereochemistry.



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbamic acid, dimethyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (9CI)
MF C27 H30 Cl N5 O7 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-3-(methylamino)-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:2)
MF C25 H28 Cl N5 O4 S . 2 Cl H

Absolute stereochemistry.



●2 HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, ethyl ester (9CI)
MF C27 H30 Cl N5 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[4-[(6-chloro-2-naphthalenyl)sulfonyl]-3-methyl-1-oxobutyl]-4-piperidinyl]-1,2-dihydro-5-methyl-
MF C26 H29 Cl N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[2-[(6-chloro-2-naphthalenyl)sulfonyl]-3-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-
MF C24 H25 Cl N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-ethyl-1,2-dihydro-7-methyl-
MF C26 H29 Cl N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[ethyl[(4-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]-
MF C25 H31 Cl N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Imidazole-5-carboxamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-
MF C22 H23 Cl N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[2-(2-hydroxyethyl)-1H-imidazol-1-yl]-1-piperidinyl]-
MF C23 H26 Cl N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-methyl-1H-imidazol-1-yl)-1-piperidinyl]-
MF C22 H24 Cl N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Oxazolidinecarboxylic acid, 2-oxo-3-[1-[2-(phenylsulfonyl)acetyl]-4-piperidinyl]-, ethyl ester
MF C19 H24 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Oxazolidinone, 5-methyl-3-[1-[2-[(2-phenylethenyl)sulfonyl]acetyl]-4-piperidinyl]-
MF C19 H24 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Oxazolidinone, 3-[1-[2-(phenylsulfonyl)acetyl]-4-piperidinyl]-
MF C16 H20 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Oxazolidinone, 4-phenyl-3-[1-[2-(phenylsulfonyl)acetyl]-4-piperidinyl]-
MF C22 H24 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-(2-imino[1,4'-bipiperidin]-1'-yl)-, (2S)-
MF C23 H28 Cl N3 O4 S
CI COM

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Piperidine, 1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-(tetrahydro-4-methyl-2-oxo-1(2H)-pyrimidinyl)- (9CI)
MF C23 H28 Cl N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Pyrimidinone, 1-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]tetrahydro-
MF C22 H26 Cl N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[3-(2-hydroxyethyl)-5-thiazolidinylidene]amino]-1-piperidinyl]-
MF C23 H28 Cl N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-[5-(hydroxymethyl)-3-methyl-2(3H)-thiazolylidene]amino]-1-piperidinyl]-
MF C23 H26 Cl N3 O4 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(3,4,6,7,8,9-hexahydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-
MF C28 H33 Cl N4 O3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1H-Indole-1-carboxylic acid, 5-chloro-2-[[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]sulfonyl]-, 1,1-dimethylethyl ester
MF C27 H32 Cl N5 O6 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN β-Alanine, N-acetyl-N-propyl-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
MF C32 H38 Cl N5 O8 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Pentanoic acid, 5-(benzoylamino)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
MF C36 H38 Cl N5 O8 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-[(dimethylamino)methyl]-1,2-dihydro-
MF C26 H30 Cl N5 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbamic acid, [(2S)-2-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-3-[4-(5-

methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI)

MF C30 H36 Cl N5 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN Urea, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-

MF C25 H27 Cl N6 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[4-[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-oxobutyl]-4-piperidinyl]-1,2-dihydro-5-methyl-

MF C23 H27 Cl N4 O4 S

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-
MF C24 H25 Cl N4 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5,7-dimethyl-
MF C25 H27 Cl N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Acetamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-[(4-methyl-1H-imidazol-5-yl)methyl]-
MF C25 H29 Cl N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5H-Imidazo[1,5-a]imidazol-5-one, 6-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-6,7-dihydro-2-methyl-
MF C24 H25 Cl N4 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[2-(hydroxymethyl)-1H-imidazol-1-yl]-1-piperidinyl]-
MF C22 H24 Cl N3 O4 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(1H-imidazol-1-yl)-1-piperidinyl]-
MF C21 H22 Br N3 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 4-Oxazolidinecarboxylic acid, 2-oxo-3-[1-[2-[(2-phenylethenyl)sulfonyl]acetyl]-4-piperidinyl]-, phenylmethyl ester
MF C26 H28 N2 O7 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Oxazolidinone, 3-[1-[2-[(2-phenylethenyl)sulfonyl]acetyl]-4-piperidinyl]-4-(phenylmethyl)-
MF C25 H28 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2H-1,3-Oxazin-2-one, tetrahydro-5,5-dimethyl-3-[1-[2-(phenylsulfonyl)acetyl]-4-piperidinyl]-
MF C19 H26 N2 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN

IN 2H-1,4-Benzothiazin-3(4H)-one, 6-[(3-[1,4'-bipiperidin]-1'-yl-2-methyl-3-oxopropyl)sulfonyl]-2-methyl-
MF C23 H33 N3 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2(1H)-Pyrimidinone, 1-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]tetrahydro-
MF C22 H26 Cl N3 O5 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3(2H)-Pyridazinone, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]tetrahydro-
MF C22 H26 Cl N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 2-Imidazolidinone, 1-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-
MF C21 H24 Cl N3 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 5-Thiazolecarboxamide, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]amino]-N,4-dimethyl-
MF C24 H27 Cl N4 O4 S2



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-[5-(1-hydroxyethyl)-3-methyl-2(3H)-thiazolylidene]amino]-1-piperidinyl]-
MF C24 H28 Cl N3 O4 S2

Double bond geometry as shown.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-
MF C28 H29 Cl N4 O3 S
CI COM



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]-
MF C25 H31 Cl N4 O3 S



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN β-Alanine, N-methyl-N-(1-oxohexyl)-,
    [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-
    piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
MF C34 H42 Cl N5 O8 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Butanoic acid, 4-(acetylamino)-, [2-[1-[(2S)-3-[(6-chloro-2-
    naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-
    oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
MF C30 H34 Cl N5 O8 S

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Carbamic acid, ethyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (9CI)
MF C27 H30 Cl N5 O7 S

Absolute stereochemistry.

PAGE 1-A





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxo-2-(2-oxo-3-oxazolidinyl)propyl]-4-piperidinyl]-1,2-dihydro-5-methyl-
MF C27 H28 Cl N5 O6 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L3 252 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN Urea, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-N'-ethyl-
MF C27 H31 Cl N6 O5 S

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil cap

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	180.20	180.41

FILE 'CAPLUS' ENTERED AT 16:20:31 ON 04 NOV 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 4 Nov 2008 VOL 149 ISS 19
FILE LAST UPDATED: 3 Nov 2008 (20081103/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d his

(FILE 'HOME' ENTERED AT 16:17:26 ON 04 NOV 2008)

FILE 'REGISTRY' ENTERED AT 16:17:33 ON 04 NOV 2008
L1 STRUCTURE UPLOADED
L2 2 S L1
L3 252 S L1 SSS FULL

```
     FILE 'CAPLUS' ENTERED AT 16:20:31 ON 04 NOV 2008

=> s l3
L4            17 L3

=> s l4 and (pry<2004)
       4260092 PRY<2004
L5            12 L4 AND (PRY<2004)

=> d 1-12 ibib abs hitstr

L5   ANSWER 1 OF 12  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:251311  CAPLUS
DOCUMENT NUMBER:          148:308364
TITLE:                    Preparation of pyrazolopyrimidines as cyclin-dependent
                          kinase inhibitors
INVENTOR(S):              Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.;
                          Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams,
                          Alan; Alvarez, Carmen S.; Keertikar, Kartik M.;
                          Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent S.;
                          Fischmann, Thierry O.; Dillard, Lawrence W.; Tran,
                          Vinh D.; He, Zhenmin; James, Ray Anthony; Park,
                          Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas
                          Walsh; Kirschmeier, Paul; Bannerji, Rajat
PATENT ASSIGNEE(S):       Shering Corporation and Pharmacopeia, Inc., USA
SOURCE:                   U.S. Pat. Appl. Publ., 387 pp., Cont.-in-part of U.S.
                          Ser. No. 396,079.
                          CODEN: USXXCO
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   10
PATENT INFORMATION:

     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     --------------      ----   --------    --------------------   --------
     US 20080050384       A1    20080228    US 2007-788847         20070420 <--
     CN 1880317           A     20061220    CN 2006-10101322       20030903 <--
     US 7161003           B2    20070109    US 2003-654546         20030903 <--
     US 20070037824       A1    20070215
     US 20040209878       A1    20041021    US 2004-776988         20040211 <--
     US 7119200           B2    20061010
     ZA 2005001855        A     20060329    ZA 2005-1855           20060117 <--
     US 20070054925       A1    20070308    US 2006-396079         20060331 <--
     WO 2008130570        A1    20081030    WO 2008-US4907         20080416
          W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
             TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
          RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.:                   US 2002-408027P     P  20020904 <--
                                         US 2002-421959P     P  20021029 <--
                                         US 2003-654546      A2 20030903 <--
                                         US 2004-776988      A3 20040211
                                         US 2006-396079      B2 20060331
                                         CN 2003-824997      A3 20030903 <--
```

OTHER SOURCE(S): MARPAT 148:308364

GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical compns. comprising the compound I alone or in combination with other therapeutic agents are claimed.

IT 677789-58-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



L5 ANSWER 2 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1395785 CAPLUS
DOCUMENT NUMBER: 148:55084
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 497pp., Cont.-in-part of U.S. Ser. No. 710,644.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20070281951	A1	20071206	US 2007-788856	20070420	<--
CN 1880317	A	20061220	CN 2006-10101322	20030903	<--
US 7161003	B2	20070109	US 2003-654546	20030903	<--
US 20070037824	A1	20070215			
US 20040209878	A1	20041021	US 2004-776988	20040211	<--
US 7119200	B2	20061010			
US 20060128725	A1	20060615	US 2005-245401	20051006	<--
US 7196078	B2	20070327			
ZA 2005001855	A	20060329	ZA 2005-1855	20060117	<--
US 20070225270	A1	20070927	US 2007-710644	20070223	<--
WO 2008130569	A1	20081030	WO 2008-US4906	20080416	

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:	US 2002-408027P	P	20020904 <--
	US 2002-421959P	P	20021029 <--
	US 2003-654546	A2	20030903 <--
	US 2004-776988	A2	20040211
	US 2005-245401	A3	20051006
	US 2007-710644	A2	20070223
	CN 2003-824997	A3	20030903 <--
	US 2007-788856	A	20070420

OTHER SOURCE(S): MARPAT 148:55084

GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I, alone or in combination with other therapeutic agent, is claimed.

IT 677789-58-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



L5 ANSWER 3 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:579598 CAPLUS
DOCUMENT NUMBER: 145:62916
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Labroli, Marc; Keertikar, Kartik M.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: U.S. Pat. Appl. Publ., 1068 pp., Cont.-in-part of U.S. Ser. No. 776,988.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
US 20060128725	A1	20060615	US 2005-245401	20051006	<--
US 7196078	B2	20070327			
CN 1880317	A	20061220	CN 2006-10101322	20030903	<--
US 7161003	B2	20070109	US 2003-654546	20030903	<--
US 20070037824	A1	20070215			
US 20040209878	A1	20041021	US 2004-776988	20040211	<--
US 7119200	B2	20061010			
ZA 2005001855	A	20060329	ZA 2005-1855	20060117	<--
US 20070072881	A1	20070329	US 2006-542920	20061004	<--
AU 2006302443	A1	20070419	AU 2006-302443	20061004	
CA 2624829	A1	20070419	CA 2006-2624829	20061004	
WO 2007044449	A2	20070419	WO 2006-US38939	20061004	
WO 2007044449	A3	20070524			

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
EP 1931677 A2 20080618 EP 2006-836186 20061004
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, RS
US 20070225270 A1 20070927 US 2007-710644 20070223 <--
US 20070281951 A1 20071206 US 2007-788856 20070420 <--
MX 200804665 A 20080617 MX 2008-4665 20080407
KR 2008063796 A 20080707 KR 2008-710183 20080428
PRIORITY APPLN. INFO.: US 2002-408027P P 20020904 <--
US 2002-421959P P 20021029 <--
US 2003-654546 A2 20030903 <--
US 2004-776988 A2 20040211
CN 2003-824997 A3 20030903 <--
US 2005-245401 A2 20051006
WO 2006-US38939 W 20061004
US 2007-710644 A2 20070223
OTHER SOURCE(S): MARPAT 145:62916
GI



I



II



III

AB The title compds. [I; R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed.

IT 677789-58-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 51 THERE ARE 51 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:300422 CAPLUS

DOCUMENT NUMBER: 142:373822

TITLE: Preparation of thiazoline derivatives as FXa inhibitors

INVENTOR(S): Kubo, Keiji; Kuroita, Takanobu; Kawamura, Masaki; Sakamoto, Hiroki

PATENT ASSIGNEE(S): Takeda Pharmaceutical Company Limited, Japan

SOURCE: PCT Int. Appl., 192 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005030740	A1	20050407	WO 2004-JP14685	20040929 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1669352	A1	20060614	EP 2004-773616	20040929 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
JP 2005126428	A	20050519	JP 2004-288257	20040930 <--

US 20070010528 A1 20070111 US 2006-574048 20060512 <--
PRIORITY APPLN. INFO.: JP 2003-341430 A 20030930 <--
WO 2004-JP14685 W 20040929

OTHER SOURCE(S): MARPAT 142:373822
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted cyclic hydrocarbon group, (un)substituted heterocyclic group; X = bond, (un)substituted divalent chain hydrocarbon group; X' = bond, NR5; R5 = H, (un)substituted hydrocarbon group, etc.; Y = (un)substituted divalent hydrocarbon group; Y' = bond, carbonyl; ring A = (un)substituted nitrogenous heterocycle; Z1, Z3 = bond, (un)substituted divalent chain hydrocarbon group; Z2 = bond, NR6; R6 = H, (un)substituted hydrocarbon group, etc.; a = 0-2; ring B = II, etc.; R2 = H, halo, etc.; R3 = H, (un)substituted hydrocarbon group, etc.; R4 = (un)substituted hydrocarbon group; further details on R2, R3, R4 were provided.] were prepared For example, reaction of 1-(3-((6-chloro-2-naphthyl)sulfonyl)propionyl)piperazine, e.g., prepared from 1-piperazinecarboxylic acid tert-Bu ester, with 4-chloromethyl-1,3-thiazole-2-amine·2HCl followed by treatment with iodomethane afforded compound III·2HCl. In FXa (blood coagulation factor Xa) inhibition assays, the IC50 value of compound III·2HCl was 22 nM. Compds. I are claimed useful for the treatment of myocardial infarction, obstructive arteriosclerosis, etc. Formulations are given.

IT 849544-76-9P 849545-22-8P 849545-23-9P
849545-24-0P 849545-25-1P 849545-26-2P
849545-27-3P 849545-28-4P 849545-29-5P
849545-30-8P 849545-31-9P 849545-32-0P
849545-33-1P 849545-45-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of thiazoline derivs. as FXa inhibitors for treatment of myocardial infarction, obstructive arteriosclerosis, etc.)

RN 849544-76-9 CAPLUS
CN 6H-Pyrrolo[3,4-d]thiazol-6-one, 5-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-2,3,4,5-tetrahydro-3-methyl-2-(methylimino)-, (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-22-8 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-(3-methyl-2(3H)-thiazolylidene)amino]-1-piperidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-23-9 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-(3,4-dimethyl-2(3H)-thiazolylidene)amino]-1-piperidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-24-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-(3,5-dimethyl-2(3H)-thiazolylidene)amino]-1-piperidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-25-1 CAPLUS
CN 3(2H)-Thiazoleacetamide, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]imino]-, (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-26-2 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-[3-(2-hydroxyethyl)-2(3H)-thiazolylidene]amino]-1-piperidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-27-3 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-[3-(2-methoxyethyl)-2(3H)-thiazolylidene]amino]-1-piperidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-28-4 CAPLUS
CN 3(2H)-Thiazoleacetic acid, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]imino]-5-methyl-, hydrochloride (1:1), (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



● HCl

RN 849545-29-5 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-[5-(1-hydroxyethyl)-3-methyl-2(3H)-thiazolylidene]amino]-1-piperidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-30-8 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-[5-(hydroxymethyl)-3-methyl-2(3H)-thiazolylidene]amino]-1-piperidinyl]- (CA INDEX NAME)

Double bond geometry as shown.



RN 849545-31-9 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-

oxopropyl]-4-piperidinyl]imino]-2,3-dihydro-3-methyl-, ethyl ester, (2Z)-
(CA INDEX NAME)

Double bond geometry as shown.



RN 849545-32-0 CAPLUS
CN 5-Thiazolecarboxamide, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-
oxopropyl]-4-piperidinyl]imino]-2,3-dihydro-N,3,4-trimethyl-, (2Z)- (CA
INDEX NAME)

Double bond geometry as shown.



RN 849545-33-1 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(Z)-[4-
(hydroxymethyl)-3-methyl-2(3H)-thiazolylidene]amino]-1-piperidinyl]- (CA
INDEX NAME)

Double bond geometry as shown.



RN 849545-45-5 CAPLUS
CN 3H-Thiazolo[3,4-a]pyrazin-8(5H)-one,
7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-
piperidinyl]tetrahydro-3-(methylimino)-, (3Z)- (CA INDEX NAME)

Double bond geometry as shown.



IT 849548-21-6
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of thiazoline derivs. as FXa inhibitors for treatment of myocardial infarction, obstructive arteriosclerosis, etc.)
RN 849548-21-6 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[3-(2-hydroxyethyl)-5-thiazolidinylidene]amino]-1-piperidinyl]- (CA INDEX NAME)



IT 849546-68-5P 849546-74-3P 849546-79-8P
849546-82-3P 849547-00-8P 849547-04-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of thiazoline derivs. as FXa inhibitors for treatment of myocardial infarction, obstructive arteriosclerosis, etc.)
RN 849546-68-5 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-thiazolylamino)-1-piperidinyl]- (CA INDEX NAME)



RN 849546-74-3 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(4-methyl-2-thiazolyl)amino]-1-piperidinyl]- (CA INDEX NAME)



RN 849546-79-8 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(5-methyl-2-thiazolyl)amino]-1-piperidinyl]- (CA INDEX NAME)



RN 849546-82-3 CAPLUS
CN 3(2H)-Thiazoleacetic acid, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]imino]-5-methyl-, 1,1-dimethylethyl ester, (2Z)- (CA INDEX NAME)

Double bond geometry as shown.



RN 849547-00-8 CAPLUS
CN 4-Thiazolecarboxylic acid, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]amino]-, ethyl ester (CA INDEX NAME)



RN 849547-04-2 CAPLUS
CN 5-Thiazolecarboxamide, 2-[[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]amino]-N,4-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:980998 CAPLUS
DOCUMENT NUMBER: 141:379942
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor M.; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-Yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
PATENT ASSIGNEE(S): Schering Corporation, USA; Pharmacopeia, Inc.
SOURCE: U.S. Pat. Appl. Publ., 1044 pp., Cont.-in-part of U.S. Ser. No. 654,546.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 20040209878	A1	20041021	US 2004-776988		20040211	<--
US 20040209878	A1	20041021	US 2004-776988		20040211	<--
PRIORITY APPLN. INFO.:			US 2002-408027P	P	20020904	<--
			US 2002-421959P	P	20021029	<--
			US 2003-654546	A2	20030903	<--
			US 2004-776988	A	20040211	

GI



I



II



III

AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. [This abstract record is one of 3 records for this document necessitated by the large number of index entries required to fully index the document and publication system constraints.]

IT 677789-58-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



L5 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:718536 CAPLUS
DOCUMENT NUMBER: 141:243546
TITLE: Preparation of N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors
INVENTOR(S): Alegria, Larry Andrew; Chong, Wesley Kwan Mung; Chu, Shaosong; Duvadie, Rohit Kumar; Li, Lin; Romines, William Henry, III; Yang, Yi
PATENT ASSIGNEE(S): Pfizer Inc., USA
SOURCE: PCT Int. Appl., 307 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074283	A1	20040902	WO 2004-IB433	20040209 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2516234	A1	20040902	CA 2004-2516234	20040209 <--
EP 1597256	A1	20051123	EP 2004-709302	20040209 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007618	A	20060221	BR 2004-7618	20040209 <--
JP 2006518368	T	20060810	JP 2006-502453	20040209 <--
US 20050101595	A1	20050512	US 2004-783887	20040220 <--
MX 2005PA08878	A	20051005	MX 2005-PA8878	20050819 <--

PRIORITY APPLN. INFO.: US 2003-448843P P 20030221 <--
WO 2004-IB433 W 20040209

OTHER SOURCE(S): MARPAT 141:243546
GI



I



II

AB The title aminothiazole compds. with N-containing cycloalkyl at the 2-amino position [I; N-containing heterocyclyl = (un)substituted N-containing 3-10 membered heterocyclyl; R1 = H, alkyl, alkenyl, alkoxy, etc.; R2 = (un)substituted alkyl, cycloalkyl, alkoxy, aryl, 4-10 membered heterocyclyl] and their pharmaceutically acceptable prodrugs or salts which modulate and/or inhibit the cell proliferation and activity of protein kinases, were prepared Thus, reacting [4-amino-2-(piperidin-4-ylamino)thiazol-5-yl](2,6-difluorophenyl)methanone (preparation given) with 1-methylpiperidine-4-carboxylic acid afforded 65% II which showed Ki of 0.46 μM against CDK2, Ki of 0.13 μM against CDK4, and IC50 of >5 μM in HCT-116 assay for cell growth inhibition. Biol. data were given for over 1100 compds. I. The pharmaceutical compns. comprising the compound I are claimed.

IT 750579-19-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-heterocyclyl-substituted amino-thiazole derivs. as protein kinase inhibitors)

RN 750579-19-2 CAPLUS

CN Ethanone, 1-[4-[[4-amino-5-(2,6-difluorobenzoyl)-2-thiazolyl]amino]-1-piperidinyl]-2-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:467881 CAPLUS
DOCUMENT NUMBER: 141:38631
TITLE: Imidazole derivative, process for producing the same, and use
INVENTOR(S): Kubo, Keiji; Kuroita, Takanobu; Imaeda, Yasuhiro; Kawamura, Masaki
PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
SOURCE: PCT Int. Appl., 318 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048363	A1	20040610	WO 2003-JP14793	20031120 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2507026	A1	20040610	CA 2003-2507026	20031120 <--
AU 2003284596	A1	20040618	AU 2003-284596	20031120 <--
EP 1564213	A1	20050817	EP 2003-774086	20031120 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2004182730	A	20040702	JP 2003-392992	20031121 <--
US 20070004736	A1	20070104	US 2006-535268	20060519 <--
PRIORITY APPLN. INFO.:			JP 2002-338939 A	20021122 <--
			WO 2003-JP14793 W	20031120 <--

OTHER SOURCE(S): MARPAT 141:38631
GI

I

AB Imidazole derivs. represented by the formula (I) [wherein R = each optionally substituted cyclic hydrocarbon group or heterocyclic group; W = a bond, optionally substituted divalent chain hydrocarbon group; X = optionally substituted divalent hydrocarbon group; Y = CO, S(O), S(O)2, a bond; ring A = each optionally substituted pyrrolidine ring, piperidine ring, or perhydroazepine ring; Z1, Z3 = each independently a bond or optionally substituted divalent chain hydrocarbon group; Z2 = N(R1), O, S(O), S(O)2, CO, CH(R1), a bond; ring B = an optionally substituted imidazole ring, provided that a substituent of the imidazole ring represented by B may be bonded to R1 to form an optionally substituted ring; m = 0, 1, 2] are prepared These imidazole derivs. are inhibitors of activated blood coagulation factor X (FXa) and useful as anticoagulants for the prevention and/or treatment of myocardial infarction, cerebral infarction, deep venous thrombosis, pulmonary thromboembolism and embolism, obstructive arteriosclerosis, economy class syndromes,

thromboembolism and embolism during or after surgery, or the second onset of deep venous thrombosis. Thus, 5-methyl-2-(4-piperidinyl)-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one was condensed with 3-[(6-chloro-2-naphthyl)sulfonyl]propionic acid using HOBt, Et3N, and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride in CH2Cl2 to give 52% 2-[1-[3-[(6-chloro-2-naphthyl)sulfonyl]propanoyl]-4-piperidinyl]-5-methyl-1,2-dihydro-3H-imidazo[1,5-c]imidazol-3-one (II). II showed IC50 of 5.6 nM for inhibiting FXa. Pharmaceutical formulations, e.g. a gelatine capsule containing II, were described.

IT 701295-58-1P 701295-60-5P 701295-62-7P
701295-63-8P 701295-65-0P 701295-67-2P
701295-69-4P 701295-70-7P 701295-71-8P
701295-72-9P 701295-73-0P 701295-74-1P
701295-75-2P 701295-76-3P 701295-77-4P
701295-78-5P 701296-00-6P 701296-01-7P
701296-02-8P 701296-03-9P 701296-04-0P
701296-05-1P 701296-06-2P 701296-07-3P
701296-12-0P 701296-13-1P 701296-14-2P
701296-15-3P 701296-16-4P 701296-17-5P
701296-18-6P 701296-19-7P 701296-20-0P
701296-21-1P 701296-22-2P 701296-23-3P
701296-24-4P 701296-25-5P 701296-26-6P
701296-27-7P 701296-28-8P 701296-29-9P
701296-30-2P 701296-31-3P 701296-32-4P
701296-33-5P 701296-42-6P 701296-44-8P
701296-46-0P 701296-99-3P 701297-00-9P
701297-01-0P 701297-02-1P 701297-03-2P
701297-04-3P 701297-05-4P 701297-07-6P
701297-08-7P 701297-09-8P 701297-10-1P
701297-11-2P 701297-12-3P 701297-13-4P
701297-15-6P 701297-16-7P 701297-17-8P
701297-18-9P 701297-19-0P 701297-21-4P
701297-23-6P 701297-25-8P 701297-26-9P
701297-27-0P 701297-28-1P 701297-29-2P
701297-30-5P 701297-31-6P 701297-32-7P
701297-33-8P 701297-34-9P 701297-35-0P
701297-36-1P 701297-37-2P 701297-38-3P
701297-40-7P 701297-41-8P 701297-42-9P
701297-43-0P 701297-44-1P 701297-45-2P
701297-46-3P 701297-47-4P 701297-48-5P
701297-49-6P 701297-50-9P 701297-51-0P
701297-52-1P 701297-53-2P 701297-54-3P
701297-55-4P 701297-56-5P 701297-57-6P
701297-58-7P 701297-59-8P 701297-60-1P
701297-61-2P 701297-62-3P 701297-63-4P
701297-64-5P 701297-65-6P 701297-66-7P
701297-67-8P 701297-68-9P 701297-71-4P
701297-72-5P 701297-73-6P 701297-74-7P
701297-75-8P 701297-76-9P 701297-77-0P
701297-78-1P 701297-79-2P 701297-80-5P
701297-89-4P 701298-05-7P 701298-08-0P
701298-10-4P 701298-11-5P 701911-96-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of imidazole derivs. as inhibitors of activated blood coagulation factor X and antithrombotics)

RN 701295-58-1 CAPLUS

CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-60-5 CAPLUS
CN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-62-7 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-methyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-63-8 CAPLUS
CN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(2-methyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-65-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(4-methyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-67-2 CAPLUS
CN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(4-methyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-69-4 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2,4-dimethyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-70-7 CAPLUS
CN 1-Propanone, 3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[4-(2,4-dimethyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-71-8 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-ethyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-72-9 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[2-(1-methylethyl)-1H-imidazol-1-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 701295-73-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-propyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-74-1 CAPLUS
CN 1-Propanone, 1-[4-(2-butyl-1H-imidazol-1-yl)-1-piperidinyl]-3-[(6-chloro-2-naphthalenyl)sulfonyl]- (CA INDEX NAME)



RN 701295-75-2 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[2-(hydroxymethyl)-1H-imidazol-1-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 701295-76-3 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[2-(2-hydroxyethyl)-1H-imidazol-1-yl]-1-piperidinyl]- (CA INDEX NAME)



RN 701295-77-4 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(4,5-dimethyl-1H-imidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701295-78-5 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(2-methyl-1H-benzimidazol-1-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701296-00-6 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(7H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-3-methyl- (CA INDEX NAME)



RN 701296-01-7 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(7H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1-methyl- (CA INDEX NAME)



RN 701296-02-8 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(7H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1-ethyl- (CA INDEX NAME)



RN 701296-03-9 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(7H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1-ethyl-3-methyl- (CA INDEX NAME)



RN 701296-04-0 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-ethyl-1,2-dihydro-

(CA INDEX NAME)



RN 701296-05-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-methyl-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 701296-06-2 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(4-bromophenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701296-07-3 CAPLUS
CN 5H-Imidazo[1,5-a]imidazol-5-one, 6-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-6,7-dihydro-2-methyl- (CA INDEX NAME)



RN 701296-12-0 CAPLUS
CN 1H-Imidazole-5-carboxamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-

oxopropyl]-4-piperidinyl]- (CA INDEX NAME)



RN 701296-13-1 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(1H-imidazol-5-ylmethyl)amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-14-2 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[(2-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-15-3 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[(4-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-16-4 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[(1H-imidazol-2-ylmethyl)amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-17-5 CAPLUS
CN Acetamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-(1H-imidazol-5-ylmethyl)- (CA INDEX NAME)



RN 701296-18-6 CAPLUS
CN Methanesulfonamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-(1H-imidazol-5-ylmethyl)- (CA INDEX NAME)



RN 701296-19-7 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[ethyl[(2-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-20-0 CAPLUS
CN Acetamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-[(2-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)



RN 701296-21-1 CAPLUS
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro-3-methyl- (CA INDEX NAME)



RN 701296-22-2 CAPLUS
CN Acetamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-[(4-methyl-1H-imidazol-5-yl)methyl]- (CA INDEX NAME)



RN 701296-23-3 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[ethyl[(4-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701296-24-4 CAPLUS
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro- (CA INDEX NAME)



RN 701296-25-5 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(5,6-dihydro-3-methylimidazo[1,5-a]pyrazin-7(8H)-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701296-26-6 CAPLUS
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro-1,5-dimethyl- (CA INDEX NAME)



RN 701296-27-7 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 7-chloro-2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro- (CA INDEX NAME)



RN 701296-28-8 CAPLUS
CN Imidazo[1,5-a]pyrazin-6(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro-1-methyl- (CA INDEX NAME)



RN 701296-29-9 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(5,6-dihydro-1-methylimidazo[1,5-a]pyrazin-7(8H)-yl)-1-piperidinyl]- (CA INDEX NAME)



RN 701296-30-2 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701296-31-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 701296-32-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-

naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-1,7-dimethyl- (CA INDEX NAME)



RN 701296-33-5 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5,7-dimethyl- (CA INDEX NAME)



RN 701296-42-6 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-ethyl-1,2-dihydro-7-methyl- (CA INDEX NAME)



RN 701296-44-8 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro- (CA INDEX NAME)



RN 701296-46-0 CAPLUS
CN 2-Propenamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-N-(4-methyl-1H-imidazol-5-yl)- (CA INDEX NAME)



RN 701296-99-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-bromo-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-00-9 CAPLUS
CN 1H-Imidazo[1,5-c]imidazole-1,3(2H)-dione, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-methyl- (CA INDEX NAME)



RN 701297-01-0 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-02-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 701297-03-2 CAPLUS
CN Imidazo[1,5-a]pyrazin-8(5H)-one, 7-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-6,7-dihydro-5-hydroxy-3-methyl- (CA INDEX NAME)



RN 701297-04-3 CAPLUS
CN Imidazo[1,2-c]pyrimidin-5(6H)-one, 6-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-7,8-dihydro- (CA INDEX NAME)



RN 701297-05-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(5-chloro-1H-indol-2-yl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-07-6 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-08-7 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[2-[(6-chloro-2-naphthalenyl)sulfonyl]-3-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-09-8 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-10-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-(hydroxymethyl)- (CA INDEX NAME)



RN 701297-11-2 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 5-[(acetyloxy)methyl]-2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 701297-12-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-(hydroxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-13-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 5-[(benzoyloxy)methyl]-2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

Cl

RN 701297-15-6 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-2-methyl-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 701297-16-7 CAPLUS
CN Carbamic acid, [1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 701297-17-8 CAPLUS

CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[2-amino-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 701297-18-9 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-3,4-dihydro-2(1H)-isoquinolinyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-19-0 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[4-[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-oxobutyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Double bond geometry as shown.



RN 701297-21-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[4-[(6-chloro-2-naphthalenyl)sulfonyl]-3-methyl-1-oxobutyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-23-6 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[[2-(4-chlorophenyl)ethyl]sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-25-8 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-26-9 CAPLUS
CN Acetamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-2,2,2-trifluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-27-0 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-2-amino-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 701297-28-1 CAPLUS
CN Acetamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-29-2 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-

oxoethyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-30-5 CAPLUS
CN Methanesulfonamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-31-6 CAPLUS
CN Benzenesulfonamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-4-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-32-7 CAPLUS
CN Urea, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-N'-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-33-8 CAPLUS
CN Urea, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-34-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-35-0 CAPLUS
CN Acetamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-2-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-36-1 CAPLUS
CN Carbamic acid, [(1R)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-37-2 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxo-2-(phenylamino)propyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-38-3 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, phenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-40-7 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 2-methoxyethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-41-8 CAPLUS
CN 4-Pyridinecarboxamide, N-[(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-42-9 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-oxoethyl]-, 2-(phenylmethoxy)ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-43-0 CAPLUS
CN Carbamic acid, [(1S)-1-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-2-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-2-

oxoethyl]-, 2-chloroethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-44-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxo-2-(2-oxo-3-oxazolidinyl)propyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-45-2 CAPLUS
CN Carbamic acid, [(2S)-2-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-46-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(3S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-3-(methylamino)-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



●2 HCl

RN 701297-47-4 CAPLUS
CN Carbamic acid, cyclohexyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-48-5 CAPLUS
CN 4-Piperidinecarboxylic acid, 1-acetyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-49-6 CAPLUS
CN 1-Pyrrolidinepropanoic acid, 2-oxo-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-50-9 CAPLUS
CN 1-Pyrrolidineacetic acid, 2-oxo-, [2-[1-[(2S)-3-[(6-chloro-2-

naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-51-0 CAPLUS
CN Carbamic acid, [2-[[(6-chloro-2-naphthalenyl)sulfonyl]methyl]-3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 701297-52-1 CAPLUS
CN 1-Piperidinepropanoic acid, 2-oxo-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-53-2 CAPLUS
CN 1-Piperidineacetic acid, 2-oxo-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-54-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2R)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-55-4 CAPLUS
CN Carbamic acid, ethyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-56-5 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-[(dimethylamino)methyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-57-6 CAPLUS
CN Carbamic acid, dimethyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-58-7 CAPLUS
CN β-Alanine, N-acetyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-59-8 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-(fluoromethyl)-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-60-1 CAPLUS
CN L-Valine, N-acetyl-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-61-2 CAPLUS
CN Carbonic acid, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl 1-methylethyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-62-3 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-(hydroxymethyl)-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701297-63-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-(difluoromethyl)-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-64-5 CAPLUS
CN Acetamide, N-[[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-65-6 CAPLUS
CN Methanesulfonamide, N-[[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-66-7 CAPLUS
CN Butanoic acid, 4-(acetylamino)-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-67-8 CAPLUS
CN Pentanoic acid, 5-(benzoylamino)-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-68-9 CAPLUS
CN β-Alanine, N-(1-oxobutyl)-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-71-4 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5,7-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-72-5 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-1,2-dihydro-5-(methoxymethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 701297-73-6 CAPLUS
CN β-Alanine, N-(1-oxohexyl)-, [2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B



RN 701297-74-7 CAPLUS
CN β-Alanine, N-ethyl-N-(1-oxopropyl)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-75-8 CAPLUS
CN β-Alanine, N-ethyl-N-(1-oxobutyl)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-76-9 CAPLUS
CN β-Alanine, N-acetyl-N-methyl-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-77-0 CAPLUS
CN β-Alanine, N-acetyl-N-ethyl-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-

piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-78-1 CAPLUS
CN β-Alanine, N-methyl-N-(1-oxobutyl)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-
piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-79-2 CAPLUS
CN β-Alanine, N-methyl-N-(1-oxohexyl)-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 701297-80-5 CAPLUS
CN β-Alanine, N-acetyl-N-propyl-,
[2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-2,3-dihydro-3-oxo-1H-imidazo[1,5-c]imidazol-5-yl]methyl ester
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 701297-89-4 CAPLUS
CN Imidazo[1,2-a]pyridine-3-carboxamide, N-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5,6,7,8-tetrahydro- (CA INDEX NAME)



RN 701298-05-7 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(3,4-dihydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 701298-08-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-(3,4,6,7,8,9-hexahydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-, hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 701298-10-4 CAPLUS
CN 1-Propanone, 3-[(5-chloro-1H-indol-2-yl)sulfonyl]-1-[4-(3,4,6,7,8,9-hexahydropyrido[4',3':4,5]imidazo[1,2-a]pyridin-2(1H)-yl)-1-piperidinyl]-,

hydrochloride (1:2) (CA INDEX NAME)



●2 HCl

RN 701298-11-5 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-methyl-4-piperidinyl]-1,2-dihydro-5-methyl- (CA INDEX NAME)



RN 701911-96-8 CAPLUS
CN 5H-Imidazo[1,5-a]imidazol-5-one, 6-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-6,7-dihydro- (CA INDEX NAME)



IT 701298-60-4P 701298-62-6P 701298-63-7P
701298-64-8P 701298-82-0P 701299-44-7P
701299-62-9P 701299-64-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of imidazole derivs. as inhibitors of activated blood coagulation factor X and antithrombotics)

RN 701298-60-4 CAPLUS
CN 1-Propanone, 1-(4-amino-1-piperidinyl)-3-[(6-chloro-2-naphthalenyl)sulfonyl]- (CA INDEX NAME)



RN 701298-62-6 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[[1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701298-63-7 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[[2-methyl-1-(triphenylmethyl)-1H-imidazol-4-yl]methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701298-64-8 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[[4-methyl-1-(triphenylmethyl)-1H-imidazol-5-yl]methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701298-82-0 CAPLUS
CN 1-Propanone, 3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[4-[[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]amino]-1-piperidinyl]- (CA INDEX NAME)



RN 701299-44-7 CAPLUS
CN 1H-Indole-1-carboxylic acid, 5-chloro-2-[[3-[4-(5-methyl-3-oxo-1H-imidazo[1,5-c]imidazol-2(3H)-yl)-1-piperidinyl]-3-oxopropyl]sulfonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 701299-62-9 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[3-[(6-chloro-2-naphthalenyl)sulfonyl]-1-oxopropyl]-4-piperidinyl]-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2-dihydro- (CA INDEX NAME)



RN 701299-64-1 CAPLUS
CN 3H-Imidazo[1,5-c]imidazol-3-one, 2-[1-[(2S)-3-[(6-chloro-2-naphthalenyl)sulfonyl]-2-hydroxy-1-oxopropyl]-4-piperidinyl]-5-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]-1,2-dihydro- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:265847 CAPLUS
DOCUMENT NUMBER: 140:321370
TITLE: Preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors
INVENTOR(S): Guzi, Timothy J.; Paruch, Kamil; Dwyer, Michael P.; Doll, Ronald J.; Girijavallabhan, Viyyoor Moopil; Mallams, Alan; Alvarez, Carmen S.; Keertikar, Kartik M.; Rivera, Jocelyn; Chan, Tin-yau; Madison, Vincent; Fischmann, Thierry O.; Dillard, Lawrence W.; Tran, Vinh D.; He, Zhen Min; James, Ray Anthony; Park, Haengsoon; Paradkar, Vidyadhar M.; Hobbs, Douglas Walsh
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 609 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 10
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004022561	A1	20040318	WO 2003-XA27555	20030903 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, NI, NO, NZ, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UZ, VC, VN, YU, ZA, ZM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CN 1735614	A	20060215	CN 2003-824997		20030903	<--
CN 100376580	C	20080326				
CN 1880317	A	20061220	CN 2006-10101322		20030903	<--
ZA 2005001855	A	20060329	ZA 2005-1855		20060117	<--
PRIORITY APPLN. INFO.:			US 2002-408027P	P	20020904	<--
			US 2002-421959P	P	20021029	<--
			CN 2003-824997	A3	20030903	<--

GI



I



II



III

AB The title compds. [I R = H, alkyl, cycloalkyl, etc.; R2 = alkyl, halo, aryl, etc.; R3 = H, halo, aryl, etc.; R4 = H, halo, alkyl], useful as inhibitors of cyclin dependent kinases for treatment, prevention, inhibition, or amelioration of one or more diseases associated with the CDKs such as cancer, were prepared Thus, reacting II (preparation given) with 4-aminomethylpyridine afforded 93% III which showed IC50 of 0.020 μM and 0.029 μM against CDK2 kinase (cyclin A or cyclin E-dependent). The pharmaceutical composition comprising the compound I is claimed. This is a Part II of I-III series.

IT 677789-58-1P
RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
(preparation of pyrazolopyrimidines as cyclin-dependent kinase inhibitors)

RN 677789-58-1 CAPLUS

CN 1-Propanone, 1-[4-[[3-bromo-5-(2-chlorophenyl)pyrazolo[1,5-a]pyrimidin-7-yl]amino]-1-piperidinyl]-3-(phenylsulfonyl)- (CA INDEX NAME)



L5 ANSWER 9 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:10480 CAPLUS
DOCUMENT NUMBER: 136:85818
TITLE: Preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents
INVENTOR(S): Blumenkopf, Todd Andrew; Flanagan, Mark Edward; Munchhof, Michael John
PATENT ASSIGNEE(S): Pfizer Products Inc., USA
SOURCE: PCT Int. Appl., 86 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002000661	A1	20020103	WO 2001-IB975	20010605 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412560	A1	20020103	CA 2001-2412560	20010605 <--
EP 1294724	A1	20030326	EP 2001-934243	20010605 <--
EP 1294724	B1	20060419		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003001114	A2	20030828	HU 2003-1114	20010605 <--
HU 2003001114	A3	20041129		
BR 2001011561	A	20030909	BR 2001-11561	20010605 <--
JP 2004501922	T	20040122	JP 2002-505785	20010605 <--
JP 4068958	B2	20080326		
EE 200200711	A	20040615	EE 2002-711	20010605 <--
NZ 522364	A	20040924	NZ 2001-522364	20010605 <--
AU 784297	B2	20060302	AU 2001-60538	20010605 <--
AT 323704	T	20060515	AT 2001-934243	20010605 <--

PT 1294724	T	20060731	PT 2001-934243	20010605	<--
ES 2257410	T3	20060801	ES 2001-934243	20010605	<--
EP 1686130	A1	20060802	EP 2006-7969	20010605	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
CN 100351253	C	20071128	CN 2001-811792	20010605	<--
TW 243820	B	20051121	TW 2001-90115016	20010620	<--
US 20020068746	A1	20020606	US 2001-891028	20010625	<--
US 6696567	B2	20040224			
IN 2002DN01075	A	20050128	IN 2002-DN1075	20021030	<--
BG 107236	A	20030930	BG 2002-107236	20021031	<--
NO 2002006030	A	20021216	NO 2002-6030	20021216	<--
NO 324934	B1	20080107			
MX 2003PA00068	A	20030925	MX 2003-PA68	20021219	<--
ZA 2002010275	A	20031219	ZA 2002-10275	20021219	<--
US 20030220353	A1	20031127	US 2003-463724	20030616	<--
US 6962993	B2	20051108			
HK 1054930	A1	20080606	HK 2003-107143	20031003	<--
US 20050197349	A1	20050908	US 2005-112307	20050421	<--
US 7192963	B2	20070320			
US 20070161666	A1	20070712	US 2007-710164	20070222	<--

PRIORITY APPLN. INFO.:

US 2000-214287P	P	20000626 <--
EP 2001-934243	A3	20010605 <--
WO 2001-IB975	W	20010605 <--
US 2001-891028	A1	20010625 <--
US 2003-463724	A1	20030616 <--
US 2005-112307	A3	20050421

OTHER SOURCE(S): MARPAT 136:85818

GI



I



II

AB The title compds. [I; R1 = NR4(CH2)yR5 (wherein y = 0-2; R4 = H, alkyl, alkylsulfonyl, etc.; R5 = substituted heterocycloalkyl); R2, R3 = H, NH2, halo, etc.], useful as inhibitors of protein kinases, such as the enzyme Janus Kinase 3 (no data given), were prepared, e.g., a multi-step synthesis of II was given.

IT 384337-72-8P 384337-79-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolo[2,3-d]pyrimidines as immunosuppressive agents)

RN 384337-72-8 CAPLUS

CN Ethanone, 1-[4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-[(4-methylphenyl)sulfonyl]- (CA INDEX NAME)



RN 384337-79-5 CAPLUS
CN Ethanone, 1-[4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1-piperidinyl]-2-(3-thiazolidinylsulfonyl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:762989 CAPLUS
DOCUMENT NUMBER: 135:318419
TITLE: Synthesis of substituted bipiperidines and their use as H1 antagonists
INVENTOR(S): Lawrence, Louise; Rigby, Aaron; Sanganee, Hitesh; Springthorpe, Brian
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.
SOURCE: PCT Int. Appl., 160 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001077101	A1	20011018	WO 2001-SE751	20010405 <--

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA	2403012	A1	20011018	CA	2001-2403012	20010405 <--
EP	1274701	A1	20030115	EP	2001-920053	20010405 <--
EP	1274701	B1	20050629			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

BR	2001009922	A	20030218	BR	2001-9922	20010405 <--
CN	1433411	A	20030730	CN	2001-810683	20010405 <--
CN	1244576	C	20060308			
JP	2003530393	T	20031014	JP	2001-575574	20010405 <--
NZ	521543	A	20041029	NZ	2001-521543	20010405 <--
EP	1493743	A1	20050105	EP	2004-20599	20010405 <--
EP	1493743	B1	20080903			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR

AT	298748	T	20050715	AT	2001-920053	20010405 <--
CN	1660839	A	20050831	CN	2004-10102245	20010405 <--
AU	2001246997	B2	20070329	AU	2001-246997	20010405 <--
AT	407131	T	20080915	AT	2004-20599	20010405 <--
US	20020077337	A1	20020620	US	2001-827488	20010406 <--
US	6525070	B2	20030225			
ZA	2002007700	A	20040102	ZA	2002-7700	20020925 <--
NO	2002004774	A	20021129	NO	2002-4774	20021003 <--
MX	2002PA09885	A	20030327	MX	2002-PA9885	20021007 <--
US	20040006080	A1	20040108	US	2003-341027	20030113 <--
US	6903115	B2	20050607			
US	20040014783	A1	20040122	US	2003-436582	20030513 <--
US	7238811	B2	20070703			
HK	1051193	A1	20051028	HK	2003-103424	20030514 <--
US	20050171092	A1	20050804	US	2005-76773	20050310 <--
US	7179922	B2	20070220			
US	20070179297	A1	20070802	US	2007-732411	20070403 <--

PRIORITY APPLN. INFO.:	GB 2000-8626	A	20000408 <--
	GB 2000-19111	A	20000803 <--
	SE 2000-3664	A	20001011 <--
	CN 2001-810683	A3	20010405 <--
	EP 2001-920053	A3	20010405 <--
	WO 2001-SE751	W	20010405 <--
	US 2001-827488	A3	20010406 <--
	US 2003-341027	A1	20030113 <--
	US 2003-436582	A3	20030513 <--

OTHER SOURCE(S): MARPAT 135:318419

GI



I



II

AB Title compds. I [q, s, t = 0 - 1; n, r = 0 - 5; m, p = 0 - 2; X = CH, C(O), O, S, S(O), S(O), N-; provided that when m and p are both 1 then X is not CH; Y = NHR2, OH; T = C(O), C(S), S(O), CH2; R1 = H, alkyl, aryl, heterocyclyl; R2, R47 = H, alkyl, aryl-alkyl, CO-alkyl; R3 = alkyl, alkenyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, thioaryl, thioheterocyclyl] were prepared Examples include: data for over 600 compds., 4 solid oral dosage and 1 parenteral (general) formulations, a bioassay for Ca2+ flux, human eosinophil chemotaxis and H1 antagonism. E.g., 4-(3,4-dichlorophenoxy)piperidine was alkylated with 1-(tert-butoxycarbonyl)-4-piperidone (1,2-dichloroethane, NaBH(OAc)3, HOAc, 18 h, room temperature) to give an intermediate [1,4']bipiperidine. This intermediate was deprotected (DCM, TFA, 4 h, room temperature) and the resulting bipiperidine condensed with 3-methanesulfonylbenzoic acid (THF, PYBROP, (i-Pr)2NEt, 18 h, room temperature) to give example compound II isolated as the acetate salt. I are used in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

IT 367498-05-3P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug; synthesis of substituted bipiperidines and use as H1 antagonists)

RN 367498-05-3 CAPLUS

CN 1-Propanone, 1-[4-(3,4-dichlorophenoxy)[1,4'-bipiperidin]-1'-yl]-2-[[5-(trifluoromethyl)-2-pyridinyl]sulfonyl]- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 11 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:453019 CAPLUS
DOCUMENT NUMBER: 135:46106
TITLE: 4-Aminopiperidine derivatives, processes for their preparation, pharmaceutical compositions, and their use as medicines, specifically as somatostatin receptor ligands
INVENTOR(S): Thurieau, Christophe; Gonzalez, Jerome; Moinet, Christophe
PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.), Fr.
SOURCE: PCT Int. Appl., 193 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: French
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001044191	A1	20010621	WO 2000-FR3497	20001213 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2802206	A1	20010615	FR 1999-15724	19991214
FR 2802206	B1	20050422		
CA 2394086	A1	20010621	CA 2000-2394086	20001213 <--
EP 1286966	A1	20030305	EP 2000-993405	20001213 <--
EP 1286966	B1	20080716		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2002004515	A2	20030428	HU 2002-4515	20001213 <--
HU 2002004515	A3	20050428		
JP 2003516965	T	20030520	JP 2001-544681	20001213 <--
NZ 520071	A	20030630	NZ 2000-520071	20001213 <--
AU 779341	B2	20050120	AU 2001-28560	20001213 <--
RU 2266282	C2	20051220	RU 2002-118705	20001213 <--
AT 401308	T	20080815	AT 2000-993405	20001213 <--
US 20040006089	A1	20040108	US 2002-130924	20020523 <--
US 7115634	B2	20061003		
US 20050239796	A1	20051027	US 2005-122293	20050504 <--
US 7393861	B2	20080701		
KR 2007014235	A	20070131	KR 2007-701118	20070116 <--

PRIORITY APPLN. INFO.:			
	FR 1999-15724	A	19991214 <--
	WO 2000-FR3497	W	20001213 <--
	US 2002-130924	A3	20020523 <--
	KR 2002-707506	A3	20020612 <--

OTHER SOURCE(S): MARPAT 135:46106
GI



I II

AB The invention concerns novel 4-aminopiperidine derivs. I [R1 = alkyl, alkenyl, alkynyl, (CH2)mYZ1, (CH2)mZ2, 1-benzylpiperidin-4-yl, 2-naphthylcarbamoyl, 4-benzylpiperazin-1-yl, 2-acetamidoethyl; Z1 = alkyl or (un)substituted aryl; Z2 = cyano, cyclohexenyl, bis-Ph, cycloalkyl, (un)substituted heterocycloalkyl, aryl, heteroaryl, etc.; R2 = C(Y)NHX1, C(O)X2, SO2X3; R3 = H, (un)substituted alkyl, alkenyl, alkynyl, aralkyl, C(Y)NHX1, (CH2)nC(O)X2, SO2X3, etc.; X1 = alkyl, alkenyl, alkynyl, aryl, aralkyl, etc.; X2 = wide variety of groups; X3 = alkyl, alkenyl, phenylalkenyl, CF3, (un)substituted (hetero)aryl or -aralkyl; Y = O, S; n = 0-4; m = 1-6]. Also disclosed are methods for their preparation by parallel synthesis processes in liquid and solid phase. I have good affinity for certain sub-types of somatostatin receptors, and are particularly useful for treating pathol. conditions or diseases wherein one more somatostatin receptor sub-types are involved. Claims specifically mention acromegaly, pituitary adenoma, or endocrine gastroenteropanceatic tumors in carcinoid syndrome. A table of 778 compds. I is given, and several syntheses are described in detail. For instance, N-BOC-4-piperidone underwent reductive amination with 3,3-diphenylpropylamine and NaBH(OAc)3, followed by reaction with 3-trifluoromethylphenyl isocyanate, removal of the BOC group with CF3CO2H, and reaction with Ph isocyanate, to give title compound II. Some compds. I had sub-micromolar Ki for at least one of five tested somatostatin receptor subtypes (no data).

IT 344783-02-4P 344783-21-7P 344783-40-0P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of aminopiperidine derivs. as somatostatin receptor ligands)

RN 344783-02-4 CAPLUS

CN Glycine, N-[[[1-[1-oxo-3-(phenylsulfonyl)propyl]-4-piperidinyl][1-(phenylmethyl)-4-piperidinyl]amino]carbonyl]-, ethyl ester (CA INDEX NAME)



RN 344783-21-7 CAPLUS
CN Urea, N'-butyl-N-[1-[1-oxo-3-(phenylsulfonyl)propyl]-4-piperidinyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



RN 344783-40-0 CAPLUS
CN Thiourea, N'-[2-(4-morpholinyl)ethyl]-N-[1-[1-oxo-3-(phenylsulfonyl)propyl]-4-piperidinyl]-N-[1-(phenylmethyl)-4-piperidinyl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 12 OF 12 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:466913 CAPLUS
DOCUMENT NUMBER: 125:142726
ORIGINAL REFERENCE NO.: 125:26717a,26720a

TITLE: Muscarine antagonists
INVENTOR(S): Thompson, Wayne J.; Sugrue, Michael F.; Ransom, Richard W.; Mallorga, Pierre J.; Bell, Ian M.; Smith, Anthony M.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 125 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE	
WO 9613262	A1	19960509	WO 1995-US13710	19951024	<--
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KR, KZ, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ					
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG					
US 5574044	A	19961112	US 1994-329757	19941027	
US 5691323	A	19971125	US 1995-440153	19950512	
CA 2200468	A1	19960509	CA 1995-2200468	19951024	<--
AU 9539674	A	19960523	AU 1995-39674	19951024	<--
AU 701127	B2	19990121			
EP 786997	A1	19970806	EP 1995-937615	19951024	<--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE					
JP 2002515008	T	20020521	JP 1996-514691	19951024	<--

PRIORITY APPLN. INFO.:
US 1994-329757 A2 19941027 <--
US 1995-440153 A2 19950512 <--
WO 1995-US13710 W 19951024 <--

OTHER SOURCE(S): CASREACT 125:142726; MARPAT 125:142726

AB Compds., 1,3-dihydro-1-{1-[piperidin-4-yl]piperidin-4-yl}-2H-benzimidazol-2-ones and 1,3-dihydro-1-{4-amino-1-cyclohexyl}-2H-benzimidazol-2-ones and derivs. thereof, their preparation, method of use and pharmaceutical compns. are described. These compds. are endowed with antimuscarinic activity and are useful in the treatment and/or prevention of myopia (commonly known as nearsightedness).

IT 179323-34-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 179323-34-3 CAPLUS

CN 2H-Benzimidazol-2-one, 1,3-dihydro-1-[1'-[2-(4-pyridinylsulfonyl)acetyl][1,4'-bipiperidin]-4-yl]- (CA INDEX NAME)



=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS SINCE FILE TOTAL

	ENTRY	SESSION
FULL ESTIMATED COST	69.44	249.85

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-9.60	-9.60

STN INTERNATIONAL LOGOFF AT 16:23:12 ON 04 NOV 2008